Baxter’s Chinese JV invests $43m in intravenous products

Pharmaceuticals

Thursday, August 28, 2008 20:04:30

	Baxter’s Chinese JV invests $43m in intravenous products By STAFF EDITOR Published: June 10, 2008 04:53 PM Baxter Qiaoguang Healthcare (Guangzhou) Co, a 50:50 joint venture between Guangzhou Baiyunshan Pharmaceutical Co (000522.SZ) and US healthcare firm Baxter International (BAX.NYSE), said it will invest $43.33 million (RMB300 million) in the Guangzhou Economic and Technological Development Zone to produce world-class total parenteral nutrition (TPN) products, China Business News reported. TPN is the practice of feeding a person intravenously, bypassing the ... You are currently reading 61 words of 186 total words in this article. To continue reading this article, you must be a subscriber. Log in now. Buy this article now for $10 USD. Not a subscriber? Start your 7-day free trial now. bookmark \| digg \| Permalink \| Tell a Friend Tags for this article: US , venture	More Articles in Pharmaceuticals > Today’s Daily Briefs E-Mail Sign up for a roundup of the day’s top stories, sent every day. RELATED ARTICLES > Tianjin railway firm sells Shenzhen branch to drugmaker Apeloa subsidiaries buy Zhejiang land for drug R&D Implant developer launches Shanghai operation center Shanghai govt consolidates local drug makers Beijing drugmaker sees 1H net profit rise 30% Sinopharm denies 4Q HK IPO Fosun Pharm 1H net profit up 144%

LOGIN AGRICULTURE AND FOOD AUTOMOTIVE AVIATION BANKING, FINANCE AND INSURANCE CHEMICALS CONSUMER AND RETAIL DEMOGRAPHICS EDITOR'S BLOG ENERGY HEAVY INDUSTRY INFRASTRUCTURE AND CONSTRUCTION INVESTMENT LEGAL AND REGULATORY LOGISTICS AND TRANSPORT MACROECONOMICS NATURAL RESOURCES AND COMMODITIES PHARMACEUTICALS POLITICS REAL ESTATE STOCK MARKETS TELECOMMUNICATIONS, MEDIA AND TECHNOLOGY TEXTILES TRADE ABOUT US Affiliates Contact Us HELP Privacy Policy Terms of Use

Browse by Title
1 2 3 4 5 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z